FDA Delays Decision on Meloxicam/Rizatriptan Combo for Migraine
AXS-07 is an oral agent that consists of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug, and rizatriptan, a 5-HT1B/1D agonist.
AXS-07 is an oral agent that consists of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug, and rizatriptan, a 5-HT1B/1D agonist.
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.
The PROGRESS study compared the efficacy and safety of atogepant to placebo in 778 adults with at least a 1-year history of chronic migraine.
Elyxyb is a ready-to-use oral solution formulation of celecoxib.
The HER-MES trial included 777 adults with episodic or chronic migraine (at least 4 migraine days/month) who were treatment-naïve, not suitable for, or had previously failed up to 3 prophylactic migraine treatments.
Eprontia is approved for the treatment of partial-onset or primary generalized tonic-clonic seizures and migraine prevention.
The analysis included 64 randomized clinical trials with a total of 46,442 patients.
Results from ADVANCE showed statistically significantly greater decreases in mean monthly migraine days with atogepant compared with placebo.
Trudhesa uses proprietary technology to deliver a lower dose (0.725mg per spray) of dihydroergotamine mesylate to the upper nasal space.
The application is supported by data from the phase 3 MOMENTUM and INTERCEPT trials.